Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) – Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Frontotemporal Dementia (FTD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Frontotemporal Dementia (FTD)
- The report reviews pipeline therapeutics for Frontotemporal Dementia (FTD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Frontotemporal Dementia (FTD) therapeutics and enlists all their major and minor projects
- The report assesses Frontotemporal Dementia (FTD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Frontotemporal Dementia (FTD)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Frontotemporal Dementia (FTD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Frontotemporal Dementia (FTD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
2N Pharma ApS3RT Innovations
AcuraStem Inc
Akava Therapeutics LLC
Alchemab Therapeutics Ltd
Alector Inc
Alkermes Plc
Alteron Therapeutics LLC
Amylyx Pharmaceuticals Inc
Anavex Life Sciences Corp
ANLBio Co Ltd
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arkuda Therapeutics Inc
ArunA Bio Inc
Arvinas Inc
Asceneuron SA
Athira Pharma Inc
Augustine Therapeutics
Autifony Therapeutics Ltd
AviadoBio Ltd
Avrion Therapeutics AG
Axon Neuroscience SE
Beijing Joekai Biotechnology Co Ltd
Bioasis Technologies Inc
Biogen Inc
Biorchestra Co Ltd
Bristol-Myers Squibb Co
Caladria Therapeutics Inc
CAMP4 Therapeutics Corp
Codiak BioSciences Inc
Cogentis Therapeutics Inc
Collaborative Medicinal Development LLC
Coya Therapeutics Inc
Crucible Therapeutics Ltd
Denali Therapeutics Inc
Expansion Therapeutics Inc
Genetic Intelligence Inc
Gismo Therapeutics Inc
Herophilus
Ilios Therapeutics Inc
ImmunoBrain Checkpoint Inc
ImStar Therapeutics Inc
Life Biosciences Inc.
Locanabio Inc
medilabo RFP Inc
MeiraGTx Holdings Plc
Modulo Bio Inc
Muna Therapeutics ApS
Neurimmune Holding AG
Neuroplast BV
NeuroTau Inc
Neuvivo Inc
New York University
Nido Biosciences Inc
Oligomerix inc
Orchard Therapeutics Plc
OrphAI Therapeutics Inc
P2D Inc
Panorama Research Institute
Parkure Ltd
Passage Bio Inc
Pharma Gateway AB
Phoenixus AG
Plico Biotech Inc
Prediction BioSciences SAS
Prevail Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
PurMinds NeuroPharma Inc
QurAlis Corporation
Samsung Medical Center
SciNeuro Pharmaceuticals
Selonterra Inc
Simon Fraser University
SineuGene Therapeutics Co Ltd
Sinfonia Biotherapeutics Inc
SOLA Biosciences LLC
Sortina Pharma AB
Stealth BioTherapeutics Inc.
Takeda Pharmaceutical Co Ltd
Teitur Trophics ApS
The Chinese University of Hong Kong
Therapeutic Solutions International Inc
Tranquis Therapeutics Inc
Transposon Therapeutics Inc
UCB SA
UniQure NV
University of Florida
Vaxxinity Inc
Verge Genomics
Voyager Therapeutics Inc